Stay updated on LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.

Latest updates to the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding the CSF-1R inhibitor LY3022855 and its trial criteria, while adding new identifiers and collaborators.SummaryDifference17%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.